Please use this identifier to cite or link to this item:
|Title:||Initial and extended use of femoral versus nonfemoral double-lumen vascular catheters and catheter-related infection during continuous renal replacement therapy.||Austin Authors:||Chua, Horng-Ruey;Schneider, Antoine G;Sherry, Norelle L ;Lotfy, Nadiah;Chan, Matthew J;Galtieri, Jonathan;Wong, Geoffrey R;Lipcsey, Miklos;Matte, Cauê de Araujo;Collins, Allison L ;Garcia-Alvarez, Mercedes;Bellomo, Rinaldo||Affiliation:||Department of Intensive Care, Austin Health, Heidelberg, Victoria, Australia
Department of Surgery, Section of Anaesthesiology and Intensive Care, Uppsala University, Uppsala, Sweden.
Department of Intensive Care, Centre Hospitalo-Universitaire Vaudois, LaUSAnne, Switzerland.
Division of Nephrology, Department of Medicine, National University Hospital, National University Health System, Singapore.
Department of Microbiology and Infectious Diseases, Austin Hospital, Melbourne, Australia
Australian and New Zealand Intensive Care Society (ANZICS) Research Centre, School of Public Health and Preventive Medicine, Monash University, Melbourne, Australia
|Issue Date:||2-Jun-2014||Publication information:||American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation 2014; 64(6): 909-17||Abstract:||The risk of catheter-related infection or bacteremia, with initial and extended use of femoral versus nonfemoral sites for double-lumen vascular catheters (DLVCs) during continuous renal replacement therapy (CRRT), is unclear.Retrospective observational cohort study.Critically ill patients on CRRT in a combined intensive care unit of a tertiary institution.Femoral versus nonfemoral venous DLVC placement.Catheter-related colonization (CRCOL) and bloodstream infection (CRBSI).CRCOL/CRBSI rates expressed per 1,000 catheter-days.We studied 458 patients (median age, 65 years; 60% males) and 647 DLVCs. Of 405 single-site only DLVC users, 82% versus 18% received exclusively 419 femoral versus 82 jugular or subclavian DLVCs, respectively. The corresponding DLVC indwelling duration was 6±4 versus 7±5 days (P=0.03). Corresponding CRCOL and CRBSI rates (per 1,000 catheter-days) were 9.7 versus 8.8 events (P=0.8) and 1.2 versus 3.5 events (P=0.3), respectively. Overall, 96 patients with extended CRRT received femoral-site insertion first with subsequent site change, including 53 femoral guidewire exchanges, 53 new femoral venipunctures, and 47 new jugular/subclavian sites. CRCOL and CRBSI rates were similar for all such approaches (P=0.7 and P=0.9, respectively). On multivariate analysis, CRCOL risk was higher in patients older than 65 years and weighing >90kg (ORs of 2.1 and 2.2, respectively; P<0.05). This association between higher weight and greater CRCOL risk was significant for femoral DLVCs, but not for nonfemoral sites. Other covariates, including initial or specific DLVC site, guidewire exchange versus new venipuncture, and primary versus secondary DLVC placement, did not significantly affect CRCOL rates.Nonrandomized retrospective design and single-center evaluation.CRCOL and CRBSI rates in patients on CRRT are low and not influenced significantly by initial or serial femoral catheterizations with guidewire exchange or new venipuncture. CRCOL risk is higher in older and heavier patients, the latter especially so with femoral sites.||Gov't Doc #:||24882583||URI:||http://ahro.austin.org.au/austinjspui/handle/1/12237||DOI:||10.1053/j.ajkd.2014.04.022||URL:||https://pubmed.ncbi.nlm.nih.gov/24882583||Type:||Journal Article||Subjects:||Acute kidney injury (AKI)
acute renal failure (ARF)
catheter-related bloodstream infection (CRBSI)
continuous renal replacement therapy (CRRT)
double lumen vascular catheter
femoral venous catheter
guidewire exchange versus new venipuncture
jugular and subclavian venous catheter
nontunneled dialysis catheter
Central Venous Catheters.adverse effects.microbiology
Renal Replacement Therapy.adverse effects.instrumentation
|Appears in Collections:||Journal articles|
Show full item record
checked on Nov 29, 2022
Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.